Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent range • Sustained growth in demand for cream and remarkable uptake of foam launched in January • July 7 ...